AVANT BIO任命Maik W. Jornitz和Lukas Utiger为运营顾问，以加强投资组合的运营支持和战略增长

NEW YORK

纽约

,

，

May 26, 2026

2026年5月26日

/PRNewswire/ -- AVANT BIO, the growth equity firm investing in life science industrials and enabling technologies, today announced the appointment of Maik W. Jornitz and Lukas Utiger as Operating Advisors. In their new roles, both advisors will work alongside AVANT BIO's portfolio companies to support operational scaling, business development, and strategic growth initiatives, including service on portfolio company boards..

/PRNewswire/ -- AVANT BIO是一家专注于生命科学工业和赋能技术的成长型股权投资公司，今天宣布任命Maik W. Jornitz和Lukas Utiger为运营顾问。在他们的新职位上，两位顾问将与AVANT BIO的投资组合公司合作，支持运营扩展、业务发展以及战略增长计划，包括在投资组合公司董事会中任职。

Continue Reading

继续阅读

Lukas Utiger and Maik Jornitz

卢卡斯·乌蒂格和迈克·约恩尼茨

The appointments reflect AVANT BIO's 'We Catalyze Value' approach, in which portfolio companies leverage the firm's global network, domain expertise, and active operational engagement to accelerate growth and maximize long-term value creation. As enabling technologies become increasingly critical to the development and manufacture of next-generation therapeutics, AVANT BIO is deepening its bench of seasoned operators who can help portfolio companies translate scientific breakthroughs into scalable, commercially successful businesses..

这些任命反映了AVANT BIO的“We Catalyze Value”方法，即投资组合公司利用该公司的全球网络、领域专业知识和积极的运营参与来加速增长并实现长期价值创造的最大化。随着赋能技术对下一代疗法的开发和制造变得日益重要，AVANT BIO正在加强其经验丰富的运营团队，以帮助投资组合公司将科学突破转化为可扩展且商业上成功的业务。

'Maik and Lukas are two of the most respected figures in bioprocess and biomanufacturing globally,' said Daniella Kranjac, Founding General Partner of AVANT BIO. 'Their depth of operational experience, their networks across the strategic acquirer universe, and their track records of building and scaling life science businesses make them ideal partners for our portfolio companies.'.

“迈克和卢卡斯是全球生物工艺和生物制造领域最受尊敬的两位人物，”AVANT BIO创始普通合伙人丹妮拉·克拉尼亚克表示，“他们深厚的操作经验、在战略收购方领域的广泛人脉，以及建立和扩展生命科学企业的成功记录，使他们成为我们投资组合公司的理想合作伙伴。”

Maik W. Jornitz is the Founder and Principal Consultant of BioProcess Resources LLC and brings more than four decades of experience in bioprocessing, single-use technologies, sterile filtration, and facility design. He spent 26 years at Sartorius in roles of increasing responsibility, culminating as Senior Vice President for Global Product and Marketing Management, Bioprocess, and subsequently served for a decade as CEO and President of G-CON Manufacturing, where he helped pioneer modular cleanroom infrastructure for advanced therapeutics..

Maik W. Jornitz 是 BioProcess Resources LLC 的创始人兼首席顾问，他在生物工艺、一次性技术、无菌过滤和设施设计方面拥有四十多年的经验。他在赛多利斯工作了 26 年，担任过多个职责递增的职位，最终担任生物工艺全球产品与营销管理高级副总裁，随后在 G-CON Manufacturing 担任了十年的首席执行官和总裁，在此期间，他帮助开创了用于先进疗法的模块化洁净室基础设施。

'I am truly delighted to join the highly professional and widely respected team at AVANT BIO,' said Maik Jornitz. 'Their commitment to growth, strategic investment, and forward-looking biopharma vision creates an inspiring environment focused on innovation, quality, and long-term impact. I look forward to contributing to and supporting this exciting journey ahead.'.

“我非常高兴能加入AVANT BIO这个高度专业且广受尊敬的团队，”Maik Jornitz说道。“他们对增长、战略投资以及前瞻性的生物制药愿景的承诺，创造了一个专注于创新、质量和长期影响的鼓舞人心的环境。我期待为这段激动人心的旅程贡献力量并提供支持。”

Maik is former Chair of the Parenteral Drug Association (PDA) Board of Directors and Science Advisory Board, and has served on multiple PDA task forces. He currently serves on the boards of DIANT Pharma and Sunflower Therapeutics, and has been recognized three times on The Medicine Maker Power List as a top biopharma influencer.

Maik 曾是注射药物协会 (PDA) 董事会和科学顾问委员会的主席，并在多个 PDA 任务组中任职。他目前在 DIANT Pharma 和 Sunflower Therapeutics 的董事会任职，并三次入选《医药制造者权力榜单》，被评为生物制药领域的顶级影响力人物。

He holds an M.Eng. in Bioengineering from the University of Applied Sciences Hamburg and completed the PED program at IMD Business School in Lausanne, Switzerland..

他持有汉堡应用科技大学的生物工程硕士学位，并在瑞士洛桑的IMD商学院完成了PED项目。

Lukas Utiger brings more than three decades of executive leadership across the global CDMO and bioprocessing landscape. He spent 20 years at Lonza Group AG, where he progressed from Head of Research and Development for Exclusive Synthesis to Chief Operating Officer of Lonza Life Science Ingredients, and ultimately to Chief Operating Officer and President of Lonza Bioscience, based in Walkersville, Maryland..

卢卡斯·乌蒂格在CDMO和全球生物工艺领域拥有三十多年的行政领导经验。他在龙沙集团工作了20年，最初担任专属合成部门的研发主管，随后升任龙沙生命科学原料的首席运营官，最终成为位于马里兰州沃尔克斯维尔的龙沙生物科学的首席运营官兼总裁。

He subsequently served as President and CEO of DSM Pharmaceutical Products and DPx Fine Chemicals, leading the business through its merger with Patheon, where he then held senior leadership roles for five years, including President of Drug Substance, before continuing for more than two years at Thermo Fisher Scientific as Group Vice President, Asian Strategy, Pharma Services Group, following Thermo's acquisition of Patheon.

他随后担任了DSM制药产品公司和DPx精细化工公司的总裁兼首席执行官，领导该业务与其与Patheon的合并，并在Patheon担任了五年的高级领导职务，包括原料药总裁。在赛默飞世尔科技收购Patheon后，他又在赛默飞世尔科技继续工作了两年多，担任集团副总裁、亚洲战略、制药服务集团。

He currently leads Utiger Life Science Consulting and serves on the boards of Abzena, Aenova and Sharp Packaging Services..

他目前领导 Utiger 生命科学咨询公司，并在 Abzena、Aenova 和 Sharp 包装服务公司的董事会任职。

'It is a great pleasure to join the energetic AVANT BIO team,' said Lukas Utiger 'After many years managing large businesses globally. I am excited to engage with innovative technology startups who are scaling commercially. Our goal is to nurture faster growth and efficiency based on our extensive experience and expertise.'.

“加入充满活力的AVANT BIO团队是一件非常愉快的事情，”卢卡斯·乌蒂格说，“在多年全球管理大型企业之后，我很高兴能与那些在商业上快速扩展的创新技术初创公司合作。我们的目标是基于我们丰富的经验和专业知识，促进更快的增长和效率。”

About AVANT BIO

关于AVANT BIO

AVANT BIO LLC is a growth equity firm investing in therapeutic-enabling technologies shaping how tomorrow's therapies are discovered, developed, manufactured and delivered. With an investment focus engineered to accelerate new growth and innovation at various stages of company development, AVANT BIO is committed to amplifying value and unlocking the full potential of therapeutic enabling technologies, TechBio, and HealthTech.

AVANT BIO LLC是一家成长型股权投资公司，专注于投资推动未来治疗发现、开发、制造和交付的治疗赋能技术。通过精心设计的投资策略，AVANT BIO致力于在企业发展的各个阶段加速新增长与创新，提升价值并充分释放治疗赋能技术、TechBio和HealthTech的潜力。

For further information, including opportunities to partner, visit .

欲了解更多信息，包括合作机会，请访问。

www.avant.bio

www.avant.bio

. Follow

. 关注

AVANT BIO

生物前沿

on LinkedIn for the latest news and industry insights.

在LinkedIn上获取最新消息和行业洞察。

SOURCE AVANT BIO LLC

生物有限责任公司来源

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示